| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $0 | — | — |
| R&D Expense | $6.3M | +21.9% | +133.9% |
| SG&A Expense | $1.1M | +3.1% | -32.6% |
| Operating Income | -$7.4M | -18.6% | -69.5% |
| Income Tax | $0 | — | — |
| Net Income | -$7.3M | -16.8% | +42.5% |
| EPS (Basic) | -$0.37 | -15.6% |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $15.3M | -10.8% | +21.0% |
| Total Assets | $17.2M | -19.9% | +19.7% |
| Current Liabilities | $3.7M | +33.1% | -30.7% |
| Total Liabilities | $4.0M | +29.1% | -44.7% |
| Stockholders' Equity | $13.2M | -28.2% | +86.3% |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$16.7M | — | — |
| Financing Cash Flow | $21.4M | — | — |
| +61.9% |
| EPS (Diluted) | -$0.37 | -15.6% | +61.9% |